000			02093 a2200565 4500
005			20250516091141.0
264		0	_c20130702
008			201307s 0 0 eng d
022			_a1873-7064
024	7		_a10.1016/j.neuropharm.2012.03.029 _2doi
040			_aNLM _beng _cNLM
100	1		_aJohnson, Kari A
245	0	0	_aThe metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease. _h[electronic resource]
260			_bNeuropharmacology _cMar 2013
300			_a187-95 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAminobutyrates _xadministration & dosage
650	0	4	_aAnimals
650	0	4	_aBenzoates _xadministration & dosage
650	0	4	_aCatalepsy _xchemically induced
650	0	4	_aDisease Models, Animal
650	0	4	_aDopamine _xmetabolism
650	0	4	_aDopamine D2 Receptor Antagonists
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDyskinesia, Drug-Induced _xdrug therapy
650	0	4	_aExcitatory Amino Acid Agonists _xadministration & dosage
650	0	4	_aForelimb _xdrug effects
650	0	4	_aGlycine _xadministration & dosage
650	0	4	_aHaloperidol
650	0	4	_aInjections, Intraventricular
650	0	4	_aMale
650	0	4	_aNeostriatum _xdrug effects
650	0	4	_aParkinsonian Disorders _xdrug therapy
650	0	4	_aRats
650	0	4	_aRats, Sprague-Dawley
650	0	4	_aReceptors, Dopamine D2 _xmetabolism
650	0	4	_aReceptors, Metabotropic Glutamate _xagonists
650	0	4	_aReserpine
650	0	4	_aTime Factors
700	1		_aJones, Carrie K
700	1		_aTantawy, Mohammed N
700	1		_aBubser, Michael
700	1		_aMarvanova, Marketa
700	1		_aAnsari, M Sib
700	1		_aBaldwin, Ronald M
700	1		_aConn, P Jeffrey
700	1		_aNiswender, Colleen M
773	0		_tNeuropharmacology _gvol. 66 _gp. 187-95
856	4	0	_uhttps://doi.org/10.1016/j.neuropharm.2012.03.029 _zAvailable from publisher's website
999			_c21743938 _d21743938